Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-150 Effects on C-Nociceptor Action Potentials
NCT05418712Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pain comparing VX-150 with Placebo (2 arms). Primary endpoint: Change From Baseline in Action Potential (AP) Latency at 0.25 Hertz (Hz). Started Jun 2022; status: completed.
02
Drugs
VX-150
03
Conditions
pain
Beyond the preview
Go deeper on NCT05418712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418712.